Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer,Journal of the National Cancer Institute

当前位置： X-MOL 学术 › J. Natl. Cancer Inst. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer
Journal of the National Cancer Institute ( IF 10.3 ) Pub Date : 2020-06-17 , DOI: 10.1093/jnci/djaa087
Ben O'Leary _{1,

2} , Rosalind J Cutts ₁ , Xin Huang ₃ , Sarah Hrebien ₁ , Yuan Liu ₃ , Fabrice André ₄ , Sibylle Loibl ₅ , Sherene Loi ₆ , Isaac Garcia-Murillas ₁ , Massimo Cristofanilli ₇ , Cynthia Huang Bartlett ₃ , Nicholas C Turner _{1,

2}

Affiliation

There are no established molecular biomarkers for patients with breast cancer receiving combination endocrine and CDK4/6 inhibitor (CDK4/6i). We aimed to determine whether genomic markers in circulating tumor DNA (ctDNA) can identify patients at higher risk of early progression on fulvestrant therapy with or without palbociclib, a CDK4/6i.

中文翻译：

氟维司群联合或不联合 Palbociclib 治疗 ER+ 晚期乳腺癌早期进展的循环肿瘤 DNA 标记物

对于接受内分泌和 CDK4/6 抑制剂 (CDK4/6i) 联合治疗的乳腺癌患者，尚无确定的分子生物标志物。我们的目的是确定循环肿瘤 DNA (ctDNA) 中的基因组标记是否可以识别接受氟维司群治疗（联合或不联合 Palbociclib（一种 CDK4/6i））时早期进展风险较高的患者。

更新日期：2020-06-17

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文

全部期刊列表>>